Spyre Therapeutics, Inc. (SYRE) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$0

Net Income/Loss (FY2025)

-$155.2M

Total Assets (FY2025)

$777.8M

Total Equity (FY2025)

$715.2M

Cash Flows from Operating Activities (FY2025)

-$169.3M

Source: Spyre Therapeutics, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.